Valsartan therapy in heart failure after myocardial infarction: The role of endothelial dependent vasorelaxation

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 6, 2007, Pages 703-707

  Thai, Hoang ^a   Guarraia, David ^b   Johnson, Nicholle ^a,b   Goldman, Steven ^a,b,c   Gaballa, Mohamed A ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

Angiotensin II receptors; Conduit arteries; eNOS; Heart failure; Vasorelaxation

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; ENDOTHELIAL DEPENDENT VASORELAXATION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; VASODILATATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HEART FAILURE; MALE; MYOCARDIAL INFARCTION; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES; TIME FACTORS; VALINE; VASODILATION; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 37348999920     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318159378b     Document Type: Article

References (33)

1. Cohn JN, Tognoni G. For the Valsartan Heart Failure Trial Investigators. A randomized trial of the aniogtensin-receptor blocker valsartan in chronic heart failure. N Eng J Med. 2001;345:1667-1675.
2. 2 receptor. J Pharmacol Exper Therap. 2003;307:1171-1178.
3. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
4. Prasad A, Tupas-Habib T, Schenke WH, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation. 2000;101:2349-2354.
5. Prasad A, Halcox JP, Waclawiw MA, Quyyumi AA. Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis, J Am Coll Cardiol. 2001;38:1089-1095.
6. Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease role of superoxide dismutase, Circulation. 2001;103:799-805.
7. 1 receptor blockade on endothelial function in essential hypertension, Am J Hypertens. 2003;16:123-128.
8. 2 receptors in endothelial cells and isolated ischemic rat hearts. Pharm Pharmacol Lett. 1993;3:24-27.
9. 2 receptor requires a tyrosine protein kinase. Circulation. 1997;96:I61.
10. Hennington BS, Zhang H, Miller T, et al. Angiotensin II stimulates synthesis of endothelial nitric oxide synthase. Hypertension. 1998;31:283-288.
11. Cachofeiro V, Maseo R, Rodrigo E, et al. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension. 1995;26:236-243.
12. Maseo R, Navarro-Cid J, Munoz-Garcia R, et al. Losartan reduces phenylnephrine constrictor response in aortic rings from spontaneously hypertensive rats. Role of nitric oxide and angiotensin type 2 receptors. Hypertension. 1996;28:967-972.
13. Fonarow GC, Chelimsky-Fallick C, Warner Stevenson L, et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting-enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol. 1992;19:842-850.
14. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 1998;319:293-302.
15. Kubo SH, Recto TS, Bank AJ, et al. Endothelium dependent vasodilation is attenuated in patients with heart failure. Circulation. 1991;84:1589-1596.
16. Drexler H, Hayoz D, Munzel T, et al. Endothelial dysfunction in congestive heart failure. Am Heart J. 1993;126:761-764.
17. Katz SD, Biasucci L, Sabba C, et al. Impaired endothelium mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol. 1992;19:918-925.
18. Raya TE, Gay RG, Aguirre M, et al. The importance of venodilatation in the prevention of left ventricular dilatation after chronic large myocardial infarction in rats: a comparison of captopril and hydralazine. Circ Res. 1989;64:330-338.
19. Litwin SE, Litwin CM, Raya TE, et al. Contractility and stiffness of noninfarcted myocardium after coronary ligation in rats. Effects of chronic ACE inhibition. Circulation. 1991;83:1028-1037.
20. 2-adrenergic receptors in large arteries. J Mol Cell Cardiol. 1998;30:1037-1045.
21. Gaballa MA, Goldman S. Overexpression of endothelial nitric oxide synthase reverses the diminished vasorelaxation in the hindlimb vasculature in ischemic heart failure in vivo. J Cell Mol Cardiol. 1999a;31:1243-1252.
22. Gaballa MA, Raya TE, Hoover CA, et al. Effects of endothelial and inducible nitric oxide synthases inhibition on circulatory function in rats after myocardial infarction. J Cardiovasc Res. 1999b;42:627-635.
23. 1 receptor blockade after myocardial infarct on myocardial fibrosis, stiffness, and contractility. Am J Physiol. 1999;276:H873-H880.
24. Thai HM, Do BQ, Tran TD, et al. Aldosterone antagonism improves endothelial dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production. J Cardiac Fail. 2006;12:240-245.
25. Bayraktutan U, Ulker S. Effects of angiotensin II on nitric oxide generation in proliferating and quiescent rat coronary microvascular endothelial cells. Hypertens Res. 2003;26:749-757.
26. Tamarat R, Silvestre JS, Kubis N, et al. Endothelial nitric oxide synthase lies downstream from angiotensin II-induced angiogenesis in ischemic hindlimb. Hypertension. 2002;39:830-835.
27. Ichiki T, Labosky PA, Shiota C, et al. Effects on blood pressure and exploratory behavior of mice lacking angiotensin II type-2 receptor. Nature. 1995;2995:748-750.
28. Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension. 1996;27:760-765.
29. 2 subtype receptors in the blood pressure lowering effect of losartan in salt-restricted rats. J Hypertens. 1998;16:2039-2043.
30. 2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest. 1997;100:264-269.
31. Ghiadoni L, Virdis A, Magagna A, et al. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension. 2000;35:501-506.
32. Tran D, Phoon S, Howes L. The effects of candesartan on vascular responses to angiotensin and norepinephrine in normal volunteers. Renin Angiotensin Aldosterone Syst. 2001;2:36-39.
33. Phoon S, Howes LG. Forearm vasodilator response to angiotensin II in elderly women receiving candesartan: role of AT (2)-receptors. Renin Angiotensin Aldosterone Syst. 2002;3:36-39.